Brooke, Christopher B
Mayo Clinic
Department of Microbiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Citations 2
Virology—the path forward
Grönvall, Gigi Kwik , Lowen, Anice C. , Goodrum, Felicia , Alwine, James C. , Andersen, Kristian G. , Anthony, Simon J. , Baines, Joel D. , Banerjee, Arinjay , Broadbent, Andrew J. , Brooke, Christopher B. , Campos, Samuel K. , Caposio, Patrizia , Chan, Gary C. , Collins-McMillen, Donna , Connell, Nancy , Damania, Blossom , Daugherty, Matthew D. , Dermody, Terence S. , Galloway, Denise A. , Hartman, Amy L. , Hogue, Brenda G. , Jung, Jae U. , Karst, Stephanie M. , Laimins, Lou, Landais, Igor, Lindenbach, Brett D. , Luftig, Micah A. , Mehle, Andrew , Moscona, Anne , Münger, Karl , Nikolich‐Žugich, Janko , Popescu, Saskia , Racaniello, Vincent R. , Rice, Charles M. , Runstadler, Jonathan A. , Sapp, Martin , Scott, Rona S. , Streblow, Daniel N. , Doorslaer, Koenraad Van , White, Elizabeth , White, Timothy M. , Worobey, Michael , Yamaoka, Satoko , Rasmussen, Angela L , Gronvall, Gigi K , Lowen, Anice C , Goodrum, Felicia , Baines, Joel , Banerjee, Arinjay , Broadbent, Andrew J , Brooke, Christopher B , Campos, Samuel K , Caposio, Patrizia , Casadevall, Arturo , Chan, Gary C , Cliffe, Anna R , Damania, Blossom , Dermody, Terence S , DiMaio, Daniel , Duprex, W Paul , Greninger, Alexander L , Hartman, Amy L , Horner, Stacy M , Jung, Jae U , Kamil, Jeremy P , Laimins, Lou , Lakdawala, Seema S , Letko, Michael , Liu, Shan-Lu , Luftig, Micah , McFadden, Grant , Mehle, Andrew , Moscona, Anne , Munger, Joshua , Murphy, Eain , O'Connor, Christine M , Pekosz, Andrew , Permar, Sallie R , Pfeiffer, Julie K , Purdy, John G , Runstadler, Jonathan A , Sapp, Martin J , Scott, Rona S , Smith, Gregory A , Tibbetts, Scott A , Toth, Zsolt , Weiss, Susan R , White, Elizabeth A , Wobus, Christiane E , Yurochko, Andrew , Nikolich, Janko Z , Casadevall, Arturo , Debbink, Kari M. , Duprex, W. Paul , Emerman, Michael , Garry, Robert F. , Goldstein, Stephen A. , Greninger, Alexander L. , Hotez, Peter Jay , Morrison, Juliet , Mühlberger, Elke , Neufeldt, Christopher John , O’Connor, Christine M. , Permar, Sallie R. , Sorrell, Erin M. , Speranza, Emily E. , Wobus, Christiane E.
Journal of Virology | January 3, 2024 | Volume: 98 | Issue: 1 | Pages: No page available
ABSTRACT In the United States (US), biosafety and biosecurity oversight of research on viruses is being reappraised. Safety in virology research is paramount and oversight frameworks should be reviewed periodically. Changes should be made with care, however, to avoid impeding science that is essential for rapidly reducing and responding to pandemic threats as well as addressing more common challenges caused by infectious diseases. Decades of research uniquely positioned the US to be able to respond to the COVID-19 crisis with astounding speed, delivering life-saving vaccines within a year of identifying the virus. We should embolden and empower this strength, which is a vital part of protecting the health, economy, and security of US citizens. Herein, we offer our perspectives on priorities for revised rules governing virology research in the US.
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
Drayman, Nir , DeMarco, Jennifer K. , Jones, Krysten A. , Azizi, Saara‐Anne , Froggatt, Heather M. , Tan, Kemin , Maltseva, N. , Chen, Siquan, Nicolaescu, Vlad , Dvorkin, Steve, Furlong, Kevin, Firpo, Mason R. , Mastrodomenico, Vincent , Bruce, Emily A. , Schmidt, Madaline M. , Jedrzejczak, R. , Schuster, Brooke , Nair, Vishnu , Han, Kyu‐Yeon , O’Brien, Amornrat , Τοματσίδου, Αναστασία, Vignuzzi, Marco , Botten, Jason , Brooke, Christopher B. , Lee, Hyun , Severson, William E., Palmer, Kenneth E. , Dickinson, Bryan C. , Joachimiak, A. , Randall, Glenn , Tay, Savaş , Maltseva, Natalia Ivanovna , Kathayat, Rahul S , Bruce, Emily A , Schmidt, Madaline M , Jedrzejczak, Robert , Muñoz-Alía, Miguel Á , Schuster, Brooke , Nair, Vishnu , Han, Kyu-Yeon , Meyer, Bjoern , Vignuzzi, Marco , Botten, Jason W , Brooke, Christopher B , Lee, Hyun , Baker, Susan C , Mounce, Bryan C , Heaton, Nicholas S , Dickinson, Bryan C , Joachimiak, Andrzej , Randall, Glenn , Tay, Savaş , Furlong, Kevin, Muñoz-Alía, Miguel Ángel , Missiakas, Dominique M.
Science | July 20, 2021 | Volume: 373 | Issue: 6557 | Pages: 931-936
Targeting the main protease of SARS-CoV-2 Inside host cells, the RNA genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is translated into two polyproteins that are cleaved to give the individual viral proteins. The main viral protease, known as Mpro or 3CLpro, plays a key role in these cleavages, making it an important drug target. Drayman et al . identified eight drugs that target 3CLpro from a library of 1900 clinically safe drugs. Because of the challenge of working with SARS-CoV-2, they started by screening for drugs that inhibit the replication of a human coronavirus that causes the common cold. They then evaluated the top hits for inhibiting SARS-CoV-2 replication and for inhibiting 3CLpro. Masitinib, a broad antiviral, inhibited the main proteases of coronaviruses and picornaviruses and was effective in reducing SARS-CoV-2 replication in mice. —VV